On the other hand, TB preventive therapy is mandatory for TBI-IMID patients undergoing treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs), including TNF-α inhibitors, anti-IL-6 agents, and JAK inhibitors [5,6,7]. Here, TNF is linked to tuberculosis.